검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1)) Miltenyi Biomedicine GmbH·B-Cell Neoplasm 10 trials |
|---|---|
Overview Program | zamtocabtagene autoleucel (MB-CART2019.1) |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | CGT |
Overview Target | B-Cell Neoplasm |
Overview Indication | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker assessments |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.. Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phas… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1)) Miltenyi Biomedicine GmbH·B-Cell Neoplasm 10 trials |
|---|---|
Overview Program | zamtocabtagene autoleucel (MB-CART2019.1) |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | CGT |
Overview Target | B-Cell Neoplasm |
Overview Indication | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker assessments |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.. Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phas… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교